Updates

January 14, 2021January 11, 2021
After Diagnosis, Treatment Options Can Boost Hope

On Saturday, Nov. 2, 2019, I was informally diagnosed with ankylosing spondylitis. I had already unknowingly suffered the symptoms of AS for years. ... Read more
January 12, 2021January 12, 2021
NORD Seeks Speakers for 2021 Virtual ‘Living Rare, Living Stronger’ Forum

The National Organization for Rare Disorders (NORD) is seeking individuals willing to share real-life experiences with rare diseases to speak at its upcoming virtual ... Read more
January 11, 2021January 11, 2021
Targeting Calcium‐sensing Receptor May Help Slow Disease Progression

Targeting the calcium‐sensing receptor (CaSR), which plays a critical role in the development of bone cells, may be a therapeutic strategy to slow the ... Read more
January 4, 2021January 4, 2021
Cosentyx Shown to Reduce Fatigue for Up to 3 Years in Active AS Patients

Treatment with Cosentyx (secukinumab) reduced fatigue for up to three years in people with active ankylosing spondylitis (AS), particularly those who ... Read more
December 21, 2020December 21, 2020
Sex Differences Found in nr-axSpA Disease Severity, Treatment Response

Among people with non-radiographic axial spondyloarthritis (nr-axSpA) — a type of arthritis that mainly affects the joints of the spine — women tend to ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

March 7, 2018March 7, 2018

Cosentyx Leads to Long-Term Improvement in AS Patients, Phase 3 Trial Shows

News

Results from a Phase 3 clinical trial show that treatment with Cosentyx (secukinumab) led to fast, significant, and sustained symptom improvement in patients with active ankylosing spondylitis (AS). Improvements were particularly noticeable in patients who had never ... Read more

Updates

After Diagnosis, Treatment Options Can Boost Hope

NORD Seeks Speakers for 2021 Virtual ‘Living Rare, Living Stronger’ Forum

Targeting Calcium‐sensing Receptor May Help Slow Disease Progression

Cosentyx Shown to Reduce Fatigue for Up to 3 Years in Active AS Patients

Sex Differences Found in nr-axSpA Disease Severity, Treatment Response

Subscribe to our mailing list

Rinvoq Recommended for EU Approval to Treat Active AS

When ‘Imagined’ Pain Becomes a Real Diagnosis

Have a DIY Spa Day for Your Aches and Pains

Humira Biosimilar AVT02 Accepted for Regulatory Review in US, Europe

What My Nightly Struggle With Invisible Illness Looked Like

NORD Push for Rare Disease Advisory Councils Focus of Dec. 16 Public Meeting

Survey Finds COVID-19 Disrupted Care, Well-Being of Rare Disease Patients in Europe

Just Keep Swimming

Latest NORD Webinar Offers Insights on Starting Nonprofit, Patient Registry

Clinical Trial Data Show Durable Efficacy of Cimzia, Bimekizumab

Xeljanz Eases AS Symptoms in Phase 3 Trial

NORD Hosting ‘RareLaunch’ Workshops to Help Start Rare Disease Non-profits

Gilead Suspends Enrollment in Phase 3 Trials of Filgotinib in AS

UK Organization ‘Same But Different’ Announces ‘Glimmer of Hope’ Photo Contest Winner

Humira Boosts Work Productivity, Lessens Sleep Problems in AS, Study Finds

Telehealth ‘Helpful’ Alternative to In-person Care, Rare Disease Patients Say

COVID-19 Lockdown Led to Fewer Swiss Patients Adhering to Treatment With Little Impact on Disease Activity

AS Pain Linked With Depression, Anxiety, Stress, Study Finds

Same But Different Asks Public to Vote on ‘Glimmer of Hope’ Calendar Photos

Ankylosing Spondylitis Is Not Your Fault

Study Supports Efficacy of Cosentyx for Patients in China, Other Countries

Obesity Increases Risk of Worse Overall Health in AS, Study Reports

Cosentyx Effective in Active nr-axSpA, Phase 3 PREVENT Trial Shows

Same But Different Photo Contest Celebrates People With Rare Diseases

AbbVie Seeks FDA, EMA Approvals of Rinvoq for Active AS

Cosentyx Leads to Long-Term Improvement in AS Patients, Phase 3 Trial Shows